Seasonal allergic rhinitis
The efficacy and safety of the fluticasone/azelastine combination spray in moderate to severe seasonal allergic rhinitis were assessed in 2 randomised, double-blind studies of similar design (n=610 and n=3398). Patients were randomised for twice-daily treatment with the combination nasal spray, fluticasone nasal spray, azelastine nasal spray or placebo (vehicle) for 14 days.2,3
In both studies, the reduction from baseline in total nasal symptom score (comprising nasal congestion, runny nose, itchy nose and sneezing) was significantly greater for the combination spray than for either agent used alone or placebo.2,3
A further study (n=612) evaluated the safety and efficacy of fluticasone/azelastine in patients with chronic rhinitis (including perennial allergic rhinitis and non-allergic rhinitis) over 12 months using fluticasone as an active control.4
The combination spray resulted in significantly greater nasal symptom relief than fluticasone monotherapy up to week 28. Treatment differences remained consistent to week 52 but significance could not be established owing to decreasing sample sizes.4
Adverse effect profile
The combination spray was well tolerated, with the most commonly reported adverse effects being epistaxis, dysgeusia, dysosmia and headache.1,3
- Dymista Summary of Product Characteristics, January 2013.
- Hampel F et al. Ann Allergy Asthma Immunol 2010; 105: 168–173.
- Carr W et al. J Allergy Clin Immunol 2012; 129: 1282–9.
- Price D et al. Poster presented at Congress of European Academy of Allergy and Clinical Immunology. Geneva, Switzerland. June 2012. P32-872.
Further information: Meda